IMEMR
EMRO
Volume 3, Issue 4 (2022)
3 2022, 3(4): 167-170 |
Back to browse issues page
History
Received: 2022/11/7 | Accepted: 2022/12/28 | Published: 2022/12/10
Received: 2022/11/7 | Accepted: 2022/12/28 | Published: 2022/12/10
How to cite this article
Nikooe S, Ghasemi H, Zarei M R, Vakilpour H, Alipoor B. Association between the ACE I/D Variant and COVID-19 Susceptibility and Severity; a Meta-Analysis. 3 2022; 3 (4) :167-170
URL: http://jccs.daneshafarand.org/article-8-87094-en.html
URL: http://jccs.daneshafarand.org/article-8-87094-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Student Research Committee, Yasuj University of Medical Sciences, Yasuj, Iran
2- Department of Basic Sciences, School of Medicine, Abadan University of Medical Sciences, Abadan, Iran
3- Department of Laboratory Sciences, Faculty of Paramedicine, Yasuj University of Medical Sciences, Yasuj, Iran
4- Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
2- Department of Basic Sciences, School of Medicine, Abadan University of Medical Sciences, Abadan, Iran
3- Department of Laboratory Sciences, Faculty of Paramedicine, Yasuj University of Medical Sciences, Yasuj, Iran
4- Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
Abstract (3937 Views)
Aims: Several studies investigated the association of ACE I/D polymorphism with the risk and severity of COVID-19 infection. However, the information in each of the published studies is limited, and the results were inconsistent or even contradictory. Accordingly, this meta-analysis evaluated the association between ACE I/D polymorphism and COVID-19 susceptibility and severity.
Materials & Methods: Two investigators independently searched the PubMed, Embase, Google Scholar, Scopus, and Science Direct databases. Five studies including 1029 cases and 3561 controls were retrieved to evaluate the association between ACE I/D polymorphism and the risk of COVID-19. Furthermore, a meta-analysis of the correlation between the ACE I/D variant and the severity of infection covered 5 case-control studies, including 264 sever-cases and 447 mild cases.
Findings: There was no association between the ACE I/D variant in all genetic models and COVID-19 susceptibility. However, our analysis revealed that there was a significant association between ACE I/D variant in the allele contrast (95% CI=0.5291-0.8353; p<0.001), recessive (95% CI=0.4268-0.9172; p=0.01) and dominant (95% CI=0.3974-0.8092; p=0.001) models and severity of COVID-19.
Conclusion: ACE I/D polymorphism is associated with the severity of COVID-19 infection. There is no association between the ACE I/D variant in all genetic models and COVID-19 susceptibility.
Materials & Methods: Two investigators independently searched the PubMed, Embase, Google Scholar, Scopus, and Science Direct databases. Five studies including 1029 cases and 3561 controls were retrieved to evaluate the association between ACE I/D polymorphism and the risk of COVID-19. Furthermore, a meta-analysis of the correlation between the ACE I/D variant and the severity of infection covered 5 case-control studies, including 264 sever-cases and 447 mild cases.
Findings: There was no association between the ACE I/D variant in all genetic models and COVID-19 susceptibility. However, our analysis revealed that there was a significant association between ACE I/D variant in the allele contrast (95% CI=0.5291-0.8353; p<0.001), recessive (95% CI=0.4268-0.9172; p=0.01) and dominant (95% CI=0.3974-0.8092; p=0.001) models and severity of COVID-19.
Conclusion: ACE I/D polymorphism is associated with the severity of COVID-19 infection. There is no association between the ACE I/D variant in all genetic models and COVID-19 susceptibility.
Keywords:
Send email to the article author